Tobira Therapeutics Inc.'s CENTAUR trial may have failed on the primary endpoint, but the firm argues that the success on a key secondary endpoint of its Phase IIb study of cenicriviroc in NASH fits FDA's expressed standards for approval.
On July 25, Tobira announced that cenicriviroc (CVC), its dual CCR2/CCR5 inhibitor, missed the primary endpoint of improvement in the...





